CNS Cancer
13
2
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.7%
1 terminated out of 13 trials
90.9%
+4.4% vs benchmark
0%
0 trials in Phase 3/4
50%
5 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (13)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
The Registry of Oncology Outcomes Associated with Testing and Treatment
Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
Imaging Brain Tumors With FACBC and Methionine
Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9
Study of D-Methadone in Patients With Chronic Pain
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
Spectroscopy With Surface Coils and Decoupling
Language Function in Patients With Brain Tumors